

Ivy Asserts Cancer Theory Would Be Accepted if Report Not Prejudiced

Editor's note: Following is the last in a series of five articles on Dr. Andrew C. Ivy and Krebiozen as a cure for cancer.

By DELOS SMITH
United Press Science Editor
Copyright 1957 by United Press
New York—Dr. Andrew C. Ivy's maximum claim for Krebiozen is that it is "biologically active against cancer in man." He asserts this would now be accepted by all his medical colleagues if two officials of the American Medical Association had not "prejudiced" the medical world with the 100-case report back in 1951.



Delos Smith, United Press Science Editor, says the medical world with the 100-case report back in 1951.

He means that when injected by needle into muscles of cancer patients it will sometimes help the patients and harm their cancers. The first is a "subjective" response—the patients feel better, their appetites improve, their pain diminishes or disappears, they become active. The latter is an "objective" response—the malignant tumors become measurably smaller.

Ivy grants that six of the seven doctors who provided the 100-case reports were sincere and honorable. But he points out that at the time little was known about how much a workable dose of Krebiozen or how often the doses should be injected. Many of the 100 patients were dying and died before they could be given enough Krebiozen for an effect to show.

Publicize "Miracle Cases"
If you intend forming an opinion, you must keep firmly in mind that individual "miracles" in cancer mean nothing. Krebiozen's lay enthusiasts have publicized "miracle cases" in patients who had any of the proven treatments and in patients who had no treatment at all.

It is well known that far-advanced patients respond "subjectively" to any treatment, no matter what, while their cancers advance inexorably and kill them.

Ivy accepts this. All cancer experts do. His contention is that "objective" improvements have occurred too frequently for them to have been due to factors other than Krebiozen. As for "subjective" improvements he has one series of patients who did not know they were getting a new treatment, and another series of patients who did know. Subjective improvement occurred in one series as often as in the other.

All but seven Krebiozen-treated patients have been on the "abandoned"—that is all proven treatments had failed and they were being kept "comfortable" until they died. Therefore, Ivy points out, it is not surprising that Krebiozen has produced "objective" response in a relatively small percentage. The big point is, he maintains, "biological activity" is shown and science must investigate that activity, and understand it in order to exploit it.

Krebiozen research is carried on by the Krebiozen Foundation, 105 West Adams st., in Chicago. Any physician may obtain Krebiozen provided his patient has exhausted all of the proven treatments the physician reports the patient's physical condition in detail, and the physician reports in detail on the results of Krebiozen treatment. If the patient is able to pay, he is asked to pay \$9.50 for each ampule. If he isn't, he is asked to pay what he can—or nothing.

So far, more than 200 physicians have obtained Krebiozen for more than 750 patients and their detailed reports are on file in the foundation office. Ivy and his associates, Drs. John F. Pick and W. P. F. Phillips, have personally treated or observed more than 100 patients. From

these cases, Ivy, Pick, and Phillips have derived studies which impress the lay mind but, as this reporter found out, impress other cancer experts not at all.

Out of the 200,000 ampules containing the whole of the existing Krebiozen, 50,000 to 60,000 ampules remain. Durovic said the was financially unable to produce a new supply because of the expense.

No Longer An "Expert"

This reporter has no competence except to present the facts. Therefore, he does not so much as suggest that Ivy is right or wrong. One fact is that Ivy no longer is recognized as a "cancer expert" by his colleagues although he was before Krebiozen came along. He no longer is a director of the American Cancer Society or has any part in organized cancer research. But he remains a professor of physiology and head of the department of clinical research of a first-class university, and a physician

and medical scientist.

Of course, the reporter sought the answer to the inevitable question: Where does the controversy go from here? Ivy wants a rigidly controlled "double blind" study of over 200 advanced patients, so set up that his opponents as well as himself would be compelled to accept the results. This would cost \$50,000 to \$100,000. A new supply of Krebiozen is needed—it would cost \$400,000 to produce one, he estimated. The Durovic's commercial rights must be respected, he said. So how to get the \$400,000 is a problem.

He grants it would not be proper for tax money or public donations such as those to the American Cancer Society, to finance the Durovic's commercial and financial future.

Offers Proposal

Ivy's opponents said it was up to Ivy to prove his contentions by accepted scientific methods which he hasn't used so far and

so has proved nothing—and it was not up to them to disprove his contentions.

But at this reporter's solicitation, Mefford R. Runyon, executive vice-president of the American Cancer Society, offered this proposal, with a view toward ending the controversy one way or the other.

If the Krebiozen Foundation will ask the society for "an independent review" of the case histories it has on file, "the American Cancer Society will take the initiative of setting up a competent committee to make such a study."

This, Runyon said, would be "a necessary prelude" to a "fair evaluation" of Krebiozen by a committee of independent scientists, either the society's committee or a committee of the National Cancer Institute. Runyon said the foundation had never asked the society or the institute to support financially "an independent objective evaluation."

Two Area Youths Among Winners of Car Designs

Two Jackson county boys have been named among the nation's best model car designers and builders by Fisher Body Craftsman's guild, Detroit, Mich.

John Foley, 17, route 1, Central Point, and Larry Morin, 15, of 4459 Clover rd., Medford, won second place in their age divisions and receive \$100 in cash.

24,000 Accidents Reported in Oregon

Salem — Nearly 24,000 traffic accidents occurred on Oregon streets and highways during the first five months of this year, the traffic safety division reported today.

While the figure falls short of the number of accidents reported for the same period a year ago, safety officials said it was "only tentative and may have to be revised upward if delayed reports are received."

Injuries during the period totaled 6,042, also a slight decline from the same period in 1956.

Albacore Located Off Coast of California

Astoria — The government survey boat John R. Manning, back in port after a search for tuna, located concentrations of albacore in four places.

Dr. Joseph Graham, Honolulu, biologist for the Pacific Oceanic fisheries investigation, said albacore tuna was found in two spots off the northern California coast and in two far at sea, midway between the coast and Hawaii. Those off the coast were about 150 to 175 miles west of Cape Blanco and 60 to 70 miles west of Cape Mendocino.

**Don't Say
"Hello"
Say - -
"FILTER-FLO"**

ED RADZWEIT

"I have an exceptionally good 1957 Chevrolet 4-door V8 Bel Air on which I can give you over \$750.00 off new car price."



This real nice car is completely equipped with Power Glide, power steering, radio, heater, spotlight, whitewalls and many, many other extras.

See Me at Courtesy Chevrolet
Call Me at SP 2-6115 Days or
SP 2-9423 Evenings and I'll Come
Right Out and Let You Drive It

*Chevrolet's got
a corner on
these fine things!*

They add a lot to driving pleasure, and to longer lasting value. Yet Chevrolet's the only leading low-priced car with *any* of them . . . the only car at any price with *all* of 'em!

SHORTEST STROKE V8. Its compact design—with less power-wasting engine weight—is the key to Chevy's alive, alert performance.

BODY BY FISHER. No other low-priced car quite comes up to its craftsmanship and solid construction.

BALL-BEARING STEERING, STANDARD. It's a big reason for Chevy's sure control and handling ease.

POSITRACTION REAR AXLE.* Say one of your rear wheels is deep in mud. With Positraction, pulling power is automatically delivered to the wheel that grips, and you're on your way!

TRIPLE-TURBINE TURBOGLIDE.* From start through cruising the going couldn't be smoother. No lags or jars with triple turbines performing.

Your Chevrolet dealer will show you *everything*, and that includes all kinds of advantages—crank-operated vent windows, a real lacquer finish, the solid, road-holding ability of outrigger rear springs, even the easier loading advantage of a low-level trunk ledge. See 'em all soon. *Optional at extra cost.



MORE PEOPLE DRIVE CHEVROLETS
THAN ANY OTHER CAR

See Your Local Authorized
Chevrolet Dealer

Only franchised Chevrolet dealers
display this famous trademark



DON'T BUY ANY CAR BEFORE YOU DRIVE A CHEVY . . . ITS BEST SHOWROOM IS THE ROAD.

Poland Jazz Festival Ends With Gunshots

Warsaw, Poland — Poland's second jazz festival ended with a tattoo of gun shots Wednesday night when nearly 2,000 rock-'n-roll fans rioted in the streets of the Baltic Sea beach resort of Zoppot, it was reported today.

Youngsters stimulated by the music of American singer Bill Ramsey and a West German band danced out into the streets forming a wild mob that wrecked a restaurant. The riot ended when militiamen fired into the air scattering the dancers.

Buy At Builders Supply



QUALITY
BLOCKS
Bricks, Flues,
Drain Tile
727
W. McAndrews
Ph. SP 2-4107